Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diagnosis.

Martinez-Ciarpaglini C, Machado I, Yoshida A, Nieto G, Berbegall AP, Blanquer-Maceíras MT, Noguera R, Ferrández A, Navarro S.

Int J Surg Pathol. 2019 Mar 24:1066896919835945. doi: 10.1177/1066896919835945. [Epub ahead of print]


Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021.


Patient-Derived Xenograft Models Reveal Intratumor Heterogeneity and Temporal Stability in Neuroblastoma.

Braekeveldt N, von Stedingk K, Fransson S, Martinez-Monleon A, Lindgren D, Axelson H, Levander F, Willforss J, Hansson K, Øra I, Backman T, Börjesson A, Beckman S, Esfandyari J, Berbegall AP, Noguera R, Karlsson J, Koster J, Martinsson T, Gisselsson D, Påhlman S, Bexell D.

Cancer Res. 2018 Oct 15;78(20):5958-5969. doi: 10.1158/0008-5472.CAN-18-0527. Epub 2018 Aug 28.


Lymph microvascularization as a prognostic indicator in neuroblastoma.

Tadeo I, Gamero-Sandemetrio E, Berbegall AP, Gironella M, Ritort F, Cañete A, Bueno G, Navarro S, Noguera R.

Oncotarget. 2018 May 25;9(40):26157-26170. doi: 10.18632/oncotarget.25457. eCollection 2018 May 25.


9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.

Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ, Mazar AP.

Anticancer Drugs. 2018 Sep;29(8):717-724. doi: 10.1097/CAD.0000000000000652.


Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.

Berbegall AP, Bogen D, Pötschger U, Beiske K, Bown N, Combaret V, Defferrari R, Jeison M, Mazzocco K, Varesio L, Vicha A, Ash S, Castel V, Coze C, Ladenstein R, Owens C, Papadakis V, Ruud E, Amann G, Sementa AR, Navarro S, Ambros PF, Noguera R, Ambros IM.

Br J Cancer. 2018 May;118(11):1502-1512. doi: 10.1038/s41416-018-0098-6. Epub 2018 May 14.


1p36 deletion results in a decrease in glycosaminoglycans which is associated with aggressiveness in neuroblastic tumors.

Tadeo I, Gamero-Sandemetrio E, Berbegall AP, Navarro S, Cañete A, Noguera R.

Histol Histopathol. 2018 May;33(5):487-495. doi: 10.14670/HH-11-947. Epub 2017 Nov 23.


A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors.

Tadeo I, Berbegall AP, Navarro S, Castel V, Noguera R.

Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26449. Epub 2017 Jan 25.


Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort.

Tadeo I, Berbegall AP, Castel V, García-Miguel P, Callaghan R, Påhlman S, Navarro S, Noguera R.

Br J Cancer. 2016 Aug 9;115(4):480-9. doi: 10.1038/bjc.2016.210. Epub 2016 Jul 14.


Diagnostic implications of intrapatient genetic tumor heterogeneity.

Berbegall AP, Navarro S, Noguera R.

Mol Cell Oncol. 2015 Sep 11;3(2):e1079671. doi: 10.1080/23723556.2015.1079671. eCollection 2016 Mar.


Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.

Braekeveldt N, Wigerup C, Tadeo I, Beckman S, Sandén C, Jönsson J, Erjefält JS, Berbegall AP, Börjesson A, Backman T, Øra I, Navarro S, Noguera R, Gisselsson D, Påhlman S, Bexell D.

Cancer Lett. 2016 Jun 1;375(2):384-389. doi: 10.1016/j.canlet.2016.02.046. Epub 2016 Mar 18.


Genetic features of neuroblastic tumors associated with opsoclonus-myoclonus syndrome opens up the possibility for detection in peripheral blood.

Berbegall AP, López-Almaraz R, Navarro S, Noguera R.

Expert Rev Neurother. 2016 May;16(5):465-7. doi: 10.1586/14737175.2016.1163221. Epub 2016 Apr 6. No abstract available.


Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors.

Tadeo I, Bueno G, Berbegall AP, Fernández-Carrobles MM, Castel V, García-Rojo M, Navarro S, Noguera R.

Oncotarget. 2016 Apr 12;7(15):19935-47. doi: 10.18632/oncotarget.7661.


Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.


Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Berbegall AP, Villamón E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Cañete A, Castel V, Navarro S, Noguera R.

Oncogene. 2016 Mar 17;35(11):1423-32. doi: 10.1038/onc.2015.200. Epub 2015 Jun 29.


Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.


Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.

Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, Jonson T, Börjesson A, Backman T, Tadeo I, Berbegall AP, Ora I, Navarro S, Noguera R, Påhlman S, Bexell D.

Int J Cancer. 2015 Mar 1;136(5):E252-61. doi: 10.1002/ijc.29217. Epub 2014 Oct 7.


Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration.

Berbegall AP, Villamón E, Tadeo I, Martinsson T, Cañete A, Castel V, Navarro S, Noguera R.

Neoplasia. 2014 Jun;16(6):471-80. doi: 10.1016/j.neo.2014.05.012.


Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy.

Tadeo I, Berbegall AP, Escudero LM, Alvaro T, Noguera R.

Front Oncol. 2014 Mar 4;4:39. doi: 10.3389/fonc.2014.00039. eCollection 2014. Review.


Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma.

Tadeo I, Piqueras M, Montaner D, Villamón E, Berbegall AP, Cañete A, Navarro S, Noguera R.

Pediatr Res. 2014 Feb;75(2):302-14. doi: 10.1038/pr.2013.217. Epub 2013 Nov 11.


Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.

Villamón E, Berbegall AP, Piqueras M, Tadeo I, Castel V, Djos A, Martinsson T, Navarro S, Noguera R.

PLoS One. 2013;8(1):e53740. doi: 10.1371/journal.pone.0053740. Epub 2013 Jan 14.


NeuPAT: an intranet database supporting translational research in neuroblastic tumors.

Villamón E, Piqueras M, Meseguer J, Blanquer I, Berbegall AP, Tadeo I, Hernández V, Navarro S, Noguera R.

Comput Biol Med. 2013 Mar;43(3):219-28. doi: 10.1016/j.compbiomed.2012.11.011. Epub 2013 Jan 4.


Comparative study of MLPA-FISH to determine DNA copy number alterations in neuroblastic tumors.

Villamón E, Piqueras M, Berbegall AP, Tadeo I, Castel V, Navarro S, Noguera R.

Histol Histopathol. 2011 Mar;26(3):343-50. doi: 10.14670/HH-26.343.


Supplemental Content

Loading ...
Support Center